Endo Health price target lowered to $36 from $42 at Stifel Stifel reduced its price target on Endo Health after the FDA denied the company's Citizen Petition on OpanaER. The firm was surprised by the FDA's decision ,and thinks the company will now have to restructure, but keeps a Buy rating based on valuation.
Endo rallies amid talk of conference cancellation Shares of Endo International are rallying 2% amid talk the company cancelled out of Leerink's conference next week. Endo has no events listed on its website and Bloomberg just reported that according to sources, the company cancelled its appearance at the conference. Shares of Endo are up $1.25 to $55.40 in afternoon trading.